Cardiol Therapeutics Reports Q3 GAAP EPS of -C$0.11, Missing Estimates by C$0.03
Cardiol Therapeutics (CRDL:CA) has reported its third-quarter financial results, revealing a GAAP earnings per share (EPS) of -C$0.11. This figure represents a miss of C$0.03 relative to market expectations. The company's recent performance follows several significant capital activities, including the launch of a $75 million At-The-Market (ATM) offering and the successful raising of over US$7 million through warrant exercises. Investors are closely monitoring upcoming clinical milestones, specifically the Q1 2027 readout for Maveric, which is viewed as a critical catalyst for the company's future valuation.
Topics: earnings report EPS miss financial results